The Biochemical Society and its publisher, Portland Press, have signed a joint statement, committing to rapid and open sharing of research data and findings relevant to the coronavirus (2019-nCoV) outbreak in China. This statement updates Wellcome’s 2016 joint statement on data sharing in public health emergencies.
With the World Health Organization declaring the coronavirus outbreak a health emergency, this statement reflects the public commitments already made by several institutions and journals over the last few days. It is aimed at researchers globally and is necessary because of the unprecedented speed and number of research papers in response to the outbreak. The intention is to ensure research findings and data relevant to this outbreak are shared rapidly and openly to help save lives.
Professor Richard Reece, Chair of the Portland Press Board and Trustee of the Biochemical Society, said: “I am pleased that Portland Press has been able to rapidly respond to this call to open up the research we have published to help inform the public health response. As a society-owned publisher, we have direct control over dissemination of the research we publish, enabling us to take swift action. With our seven journals covering a variety of research and reviews across the biosciences, I hope we can add strength and support to finding a cure.”
From today (31 January 2020), the Biochemical Society and Portland Press have made the relevant published articles free to read, and new papers relevant to the outbreak will be available via open access on publication. Authors will also be encouraged to post submitted versions of articles as preprints.
- Expanding our understanding of the role polyprotein conformation plays in the coronavirus life cycle
- A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity
- Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling
- ACE2 the Janus-faced protein – from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19
- Processing of the SARS-CoV pp1a/ab nsp7–10 region
- Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
- Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery
- Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors
- Detection methods for influenza A H1N1 virus with special reference to biosensors: A review
- SARS: clinical presentation, transmission, pathogenesis and treatment options
- The SARS coronavirus nucleocapsid protein induces actin reorganization and apoptosis in COS-1 cells in the absence of growth factors
- The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1–PKB/Akt signalling
- Programmed −1 ribosomal frameshifting in the SARS coronavirus
- Alterations of membrane curvature during influenza virus budding
- Porcine deltacoronavirus causes diarrhea in various ages of field-infected pigs in China
- SARS hCoV papain-like protease is a unique Lys48 linkage-specific di-distributive deubiquitinating enzyme
- Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation
- H2 influenza viruses: designing vaccines against future H2 pandemics
- Confronting an influenza pandemic: ethical and scientific issues
- Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis
- Pulmonary immunity to viruses
- Can we identify viruses with pandemic potential?
- Flu under the spotlight